Figure 1.

General Recommendations for Antihyperglycemic Therapy, T2DM

GLP-1 RA, glucagon-like peptide 1 receptor agonist; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SGLT2i, sodium-glucose cotransporter-2 inhibitor; SU, sulfonylurea; T2DM, type 2 diabetes mellitus; TZD, thiazolidinedione.

†Consider initial therapy at this stage when HbA_1c is 9% (75 mmol/mol).

‡Consider initial therapy at this stage when blood glucose is 300–350 mg/dL (16.7–19.4 mmol/L) and/or HbA_1c 10–12% (86–108 mmol/mol), especially if patient is symptomatic or if catabolic features (weight loss, ketosis) are present, in which case basal insulin 1 mealtime insulin is the preferred initial regimen.

§Usually a basal insulin (eg, NPH, glargine, detemir, degludec).

Reproduced from Inzucchi SE et al. Management of Hyperglycemia in Type 2 Diabetes 2015: A Patient Centered Approach, Diabetes, 38, 2015, Copyright and all rights reserved. Material from this publication has been used with the permission of American Diabetes Association.